Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells
- PMID: 24883377
- PMCID: PMC4032698
- DOI: 10.1155/2014/282147
Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells
Abstract
Early and late endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (HSCT). This review summarizes main endocrine disorders reported in literature and observed in our center as consequence of auto- and allo-HSCT and outlines current options for their management. Gonadal impairment has been found early in approximately two-thirds of auto- and allo-HSCT patients: 90-99% of women and 60-90% of men. Dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary-thyroid axis, and hypothalamus-pituitary-adrenal axis were documented as later complicances, occurring in about 10, 30, and 40-50% of transplanted patients, respectively. Moreover, overt or subclinical thyroid complications (including persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma), gonadal failure, and adrenal insufficiency may persist many years after HSCT. Our analysis further provides evidence that main recognized risk factors for endocrine complications after HSCT are the underlying disease, previous pretransplant therapies, the age at HSCT, gender, total body irradiation, posttransplant derangement of immune system, and in the allogeneic setting, the presence of graft-versus-host disease requiring prolonged steroid treatment. Early identification of endocrine complications can greatly improve the quality of life of long-term survivors after HSCT.
Figures
References
-
- Kolb HJ, Socié G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of the European cooperative group for blood and marrow transplantation and the European late effect project group. Annals of Internal Medicine. 1999;131(10):738–744. - PubMed
-
- Horowitz M. Uses and growth of hematopoetic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematoipoietic Cell Transplantation. 2nd edition. Oxford, UK: Blackwell; 1998. pp. 12–18.
-
- Roziakova L, Mladosievicova B. Endocrine late effects after hematopoietic stem cell transplantation. Oncology Research. 2010;18:607–615. - PubMed
-
- Shalet SM, Didi M, Ogilvy-Stuart AL, Schulga J, Donaldson MDC. Growth and endocrine functiom after bone marrow transplantation. Clinical Endocrinology. 1995;42(4):333–339. - PubMed
-
- Brennan BMD, Shalet SM. Endocrine late effects after bone marrow transplant. British Journal of Haematology. 2002;118(1):58–66. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
